$7.05
+0.01 (+0.14%)
Open$7.03
Previous Close$7.04
Day High$7.41
Day Low$6.95
52W High$12.60
52W Low$6.32
Volume—
Avg Volume5.7K
Market Cap28.50M
P/E Ratio0.17
EPS$40.46
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+352.6% upside
Current
$7.05
$7.05
Target
$31.91
$31.91
$24.67
$31.91 avg
$44.05
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.44M | 18.00M | 5.44M |
| Net Income | 183.42M | 461.51M | -1,283,535 |
| Profit Margin | 2,848.6% | 2,706.2% | -23.6% |
| EBITDA | -51,722,125 | -137,366,560 | -2,024,078 |
| Free Cash Flow | — | — | -1,099,827 |
| Rev Growth | -64.2% | -64.2% | +18.0% |
| Debt/Equity | 0.08 | 0.08 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |